19 research outputs found
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Characteristics and treatment patterns in patients newly diagnosed with chronic lymphocytic leukemia (CLL).
Survival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients.
Economic impact of rituximab as maintenance therapy in previously untreated follicular non-Hodgkin lymphoma.
Association of skin rash severity and overall survival in patients receiving erlotinib for pancreatic cancer in the community setting.
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL).
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab